PrP 106-126

PrP 106-126 is a synthetic peptide fragment corresponding to amino acid residues 106 to 126 of the human prion protein (PrP). As a biochemically significant region of the prion protein, this peptide has garnered considerable attention in neurodegenerative disease research due to its pivotal role in prion pathophysiology. The 106-126 sequence is known for its amyloidogenic properties and its propensity to form β-sheet-rich fibrils, making it a valuable tool for modeling prion-related aggregation and toxicity in vitro. Its unique structural and functional features have established it as a central reagent for probing the molecular underpinnings of prion diseases and for advancing the broader understanding of protein misfolding disorders.

Neurotoxicity modeling: Researchers utilize PrP 106-126 to recapitulate key aspects of prion-induced neurotoxicity in cellular and organotypic systems. The peptide is capable of inducing apoptotic and necrotic cell death in neuronal cultures, thereby serving as an experimentally tractable agent for dissecting the cellular pathways underlying prion-mediated neurodegeneration. By providing a controllable model for prion toxicity, it enables the investigation of oxidative stress responses, mitochondrial dysfunction, and calcium dysregulation associated with prion diseases.

Amyloid fibril formation studies: Due to its high propensity for self-aggregation, the 106-126 fragment is widely employed in studies of amyloid fibril formation and protein misfolding. Researchers use this peptide to monitor the kinetics of aggregation, characterize intermediate species, and assess the influence of various environmental factors on fibrillogenesis. These studies contribute to a mechanistic understanding of amyloidogenesis, offering insights that are applicable not only to prion disorders but also to related protein aggregation diseases.

Screening of anti-aggregation compounds: PrP 106-126 serves as a robust substrate in high-throughput screening assays aimed at identifying small molecules, peptides, or biological agents capable of inhibiting prion peptide aggregation or mitigating its toxic effects. By providing a reproducible and sensitive platform, the peptide facilitates the evaluation of candidate modulators, enabling the discovery and characterization of potential aggregation inhibitors for research use.

Membrane interaction research: The amphipathic nature of the 106-126 peptide allows for detailed investigation of prion-lipid interactions and membrane perturbation mechanisms. Studies employing this fragment have elucidated its ability to bind to lipid bilayers, disrupt membrane integrity, and alter ion permeability. Such research is critical for understanding the role of membrane interactions in prion pathogenesis and for exploring the biophysical basis of peptide-induced cytotoxicity.

Structure-function analysis: PrP 106-126 is frequently used in biophysical and structural studies aimed at mapping the determinants of prion protein misfolding and aggregation. Through spectroscopic, microscopic, and computational approaches, researchers analyze the conformational transitions, secondary structure preferences, and intermolecular interactions of the peptide. These analyses provide foundational knowledge that informs the rational design of experimental models and the interpretation of prion biology at the molecular level.

1. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

2. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

3. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

4. TMEM16F and dynamins control expansive plasma membrane reservoirs

5. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance